Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
26 shown of 6,204 total abstracts
  1. Abstract 92312026-06-01 · 20:15 CT · Hall B1
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    S. Tolaney, S. Peters, T. Mok · Institut Gustave Roussy
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  2. Abstract 93372026-06-04 · 21:00 CT · E450
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-925
    E. Winer, S. Tolaney, C. Robert · MD Anderson Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  3. Abstract 96092026-06-01 · 18:00 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    L. Paz-Ares, G. Curigliano · Cleveland Clinic
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  4. Abstract 93112026-06-03 · 13:15 CT · E450
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-188
    G. Curigliano, S. Antonia, J. Brahmer, et al. · Mayo Clinic
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  5. Abstract 92452026-06-01 · 21:30 CT · S100A
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    S. Antonia, A. Spira, C. Robert, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  6. Abstract 94762026-06-02 · 15:15 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with NSCLC
    J. Cortes, L. Paz-Ares, M.C. Garassino, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  7. Abstract 98432026-06-03 · 21:45 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-899 study)
    S. Peters, G. Curigliano, H. Borghaei, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  8. Abstract 96112026-06-03 · 18:15 CT · S100A
    FLAURA-658: Tagrisso (osimertinib) neoadjuvant in NSCLC
    G. Curigliano, A. Spira · Stanford Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  9. Abstract 90492026-06-02 · 18:45 CT · E450
    Quality of life outcomes with Tagrisso in patients with NSCLC
    H. Borghaei, E. Winer, N. Rizvi, et al. · Royal Marsden Hospital
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  10. Abstract 98752026-06-04 · 18:00 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-555 study)
    A. Spira, S. Modi, C. Robert, et al. · Massachusetts General Hospital
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  11. Abstract 98142026-06-02 · 19:15 CT · S406
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    S. Modi, N. Rizvi · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  12. Abstract 92342026-06-02 · 13:45 CT · Hall B1
    Quality of life outcomes with Imfinzi in patients with SCLC
    P. Schmid, H. Borghaei · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  13. Abstract 96092026-06-02 · 13:30 CT · E450
    FLAURA-629: Tagrisso (osimertinib) 3L+ in NSCLC
    G. Curigliano, S. Peters, S. Modi, et al. · Cleveland Clinic
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  14. Abstract 90152026-06-01 · 20:30 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-135 study)
    H. Rugo, M. Krop, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  15. Abstract 93172026-06-02 · 20:45 CT · S100A
    Long-term follow-up of Tecentriq adjuvant for NSCLC: IMpower-672
    J. Cortes, P. Schmid, F. Andre, et al. · University of Chicago
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  16. Abstract 95292026-06-01 · 20:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-430 study)
    C. Saura, S. Antonia, S. Peters · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  17. Abstract 92712026-06-04 · 14:30 CT · E450
    Quality of life outcomes with Imfinzi in patients with NSCLC
    F. Andre, J. Brahmer, A. Spira, et al. · Cleveland Clinic
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  18. Abstract 91732026-06-04 · 15:15 CT · E450
    Quality of life outcomes with Opdivo in patients with NSCLC
    J. Cortes, C. Saura, S. Antonia · Institut Gustave Roussy
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  19. Abstract 94492026-06-03 · 19:15 CT · S100A
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-34 study)
    P. Schmid, L. Paz-Ares, M. Krop, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  20. Abstract 98652026-06-04 · 18:45 CT · S406
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-553
    S. Peters, H. Rugo, F. Andre, et al. · University of Chicago
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  21. Abstract 93042026-06-05 · 21:15 CT · E450
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-208
    S. Modi, R. Herbst · Chinese University of Hong Kong
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  22. Abstract 93902026-06-03 · 21:45 CT · S100A
    Long-term follow-up of Opdivo 3L+ for NSCLC: CheckMate-34
    L. Paz-Ares, S. Tolaney, C. Saura · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  23. Abstract 93942026-06-05 · 14:45 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-13 study)
    C. Robert, J. Cortes, T. Mok · Chinese University of Hong Kong
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  24. Abstract 91602026-06-02 · 16:30 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with NSCLC
    R. Herbst, S. Peters, E. Winer, et al. · Royal Marsden Hospital
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  25. Abstract 97142026-06-02 · 16:30 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-75 study)
    M.C. Garassino, C. Robert, E. Winer, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  26. Abstract 90722026-06-02 · 16:15 CT · E450
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-761 study)
    L. Paz-Ares, P. Schmid, N. Rizvi · Dana-Farber Cancer Institute
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.